On August 31, 2026, AIM Immunotech Inc. entered into five exchange agreements and issued corresponding partitioned promissory notes with Streeterville Capital, LLC. Approximately $1,224,341 of a previous promissory note was converted into 5,065,840 shares of the company's common stock. This transaction satisfied the outstanding promissory note in full.
Company Information
Company
AIM ImmunoTech
Location
Ocala, Florida, United States
About
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Don't miss AIM ImmunoTech's next move
Get an email the moment AIM ImmunoTech raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contacts21 people are listed at AIM ImmunoTech. We don't have their email yet.
Predictive Intelligence
Strategic
ML-powered predictions for AIM ImmunoTech's next move
OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical